ATLANTA February 28, 2016 – Emory University School of Medicine and AKESOgen announced today their collaboration on the Emory Healthy Aging Study. The largest clinical research study ever conducted in Atlanta, the Emory Healthy Aging Study is a game changing effort to further the scientific understanding of how we age. Aiming to identify predictive markers through cutting edge technologies, the study will enable the prediction of diseases occurring more commonly in later years.
Through recruitment of thousands of study participants over the next few years, the Emory Healthy Aging Study will build an extensive database of personal health information. The data collected may also help participants, through consultation with their physician, learn more about their overall health.
As an academic medical center, Emory’s mission includes providing care for patients and researching how to provide even better care in the future. AKESOgen shares this philosophy, and is well established as one of the top College of American Pathologists (CAP) accredited providers of high quality data to both research and medical institutions. Many important medical discoveries and groundbreaking new treatments have been made at Emory, thanks to the work of Emory researchers and the contributions of study participants.
“We are delighted to be working with leading scientists at Emory on this unique and outstanding long term study on health and wellbeing which will deliver enormous benefits to the participants and the community as a whole.” commented AKESOgen’s CEO Bob Boisjoli.
“We believe our strong relationship with Emory and our excellent scientific and technical prowess in precision medicine will allow us to make important contributions to new discoveries in this exciting landmark study.” says Mark Bouzyk PhD, AKESOgen’s Chief Scientific Officer.
Over time, Emory’s diverse team of researchers will study numerous age-related diseases. Examples of these include Alzheimer’s disease, heart disease, and diabetes. AKESOgen has deep experience in precision medicine approaches in these diseases among others.
“The Emory Healthy Aging Study is an ambitious clinical research endeavor that aims to improve the lives of people so they may live healthier lives as they age,” says James Lah, MD, PhD, the principal investigator of the study and associate professor and vice-chair of the Department of Neurology at Emory.
“A study of this scale, gathering large amounts of health data across a diverse participant population, will help us learn more about a host of age-related diseases,” adds Michele Marcus, PhD, Professor of Epidemiology at Emory and a lead investigator of the study.
About the Emory Healthy Aging Study
The Emory Healthy Aging Study is the largest clinical research study ever conducted at Emory University. It is an effort to further the scientific understanding of how people age, and to learn more about diseases that occur more commonly in later years. The Emory Healthy Aging Study seeks to enroll 100,000 people and anyone 18 years of age or older who is a U.S. resident is eligible to participate. For more information, visit https://healthyaging.emory.edu.
About AKESOgen, Inc.
AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) and Pathology. For more information, visit www.akesogen.com.
Marissa Cooke, Director, Marketing and Business Development AKESOgen, Inc. +1 770-542-0890, or email@example.com